department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Orbactiv · pharmadog

pharmadog
drugs
Orbactiv

drug

patient view →

oritavancin diphosphate

Marketedupdated 2mo ago

by A. Menarini Industrie Farmaceutiche Riunite Srl

Approved

community read0 votes

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

brand

Orbactiv

generic

oritavancin diphosphate

indication

Skin And Skin Structure Infections (SSSI) Caused By Bacteria

phase

marketed

Data sources

ClinicalTrials.gov

last refreshed 3m ago

Found something off?

🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

Patent cliff

source: FDA Orange Book

first barrier falls

Aug 29, 2029

~3.1 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (4)

Jul 16, 2035formulationUS 9649352
Apr 26, 2030method-of-use (U-1569)US 96820613.8y
Aug 29, 2029method-of-use (U-4398)US 125148993.1y
Aug 29, 2029method-of-use (U-1570)US 84205923.1y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Trials studying oritavancin diphosphate

phase2Study to Evaluate the Safety of Intravenous Oritavancin for the Treatment of Children With Skin Infectionscompletedn=118
phase1A Study to Assess the Cardiac Safety of Oritavancin in Healthy Participantscompletedn=150
phase1Drug-Drug Interaction Potential of Orbactiv (Oritavancin) Co-Administered With Warfarin in Healthy Subjectscompletedn=36
phase1Open Label Study Evaluating the Effects of a Single Oritavancin Infusion on Cytochrome P450 in Healthy Volunteerscompletedn=16